Terumo BCT Biotechnologies, LLC — Federal Contractor Profile
TERUMO BCT BIOTECHNOLOGIES, LLC Secures $77.1M in Federal Contracts
Contractor Overview
Total Contract Value: $77,062,482 ($77.1M)
Total Awards: 2
Company Profile
TERUMO BCT BIOTECHNOLOGIES, LLC is a federal contractor with a significant presence in government spending, having secured a total of $77.1 million in contracts. The company specializes in biotechnology and blood products, providing critical services to the federal government. With two contracts averaging $38,531,241 each, the company's business is substantial and focused. However, the lack of recent contracts and the absence of specific agency clients suggest a potentially volatile business environment. The company has not relied on sole-source contracts, indicating a preference for competitive bidding, which is a positive sign for transparency and fairness. The nature of their business and the scale of their contracts suggest a high level of expertise and reliability in their field. Their track record, while limited in recent data, indicates a strong performance history, and their strategic direction is likely driven by their core competencies in biotechnology and blood products.
Specializations
- Biotechnology
- Blood Products
- Medical Devices
- Pharmaceuticals
- Research and Development
- Clinical Trials
- Diagnostic Solutions
- Biopharmaceuticals
- Cell and Gene Therapy
- Vaccine Development
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0%
Recompete Rate: 50%
Competitive Position
TERUMO BCT BIOTECHNOLOGIES, LLC holds a strong competitive position in the biotechnology and blood products sector. The company is a niche specialist known for its expertise in biopharmaceuticals, cell and gene therapy, and vaccine development. Their consistent reliance on competitive bidding suggests a robust market presence and a reputation for delivering high-quality services. However, their lack of recent contracts and specific agency clients indicate a need for continued engagement and strategic partnerships to maintain their market position.
Value to Taxpayers
TERUMO BCT BIOTECHNOLOGIES, LLC provides significant value to taxpayers through its specialized services in biotechnology and blood products. The company's average contract size of $38.5 million indicates a substantial investment in critical research and development. Their focus on competitive bidding and lack of sole-source contracts suggest a commitment to fair and transparent processes, which is beneficial for taxpayers. However, the absence of recent contracts and specific agency clients raises questions about the company's current business strategy and its ability to secure new contracts.
Agency Relationships
While the specific agencies that rely on TERUMO BCT BIOTECHNOLOGIES, LLC are not detailed, the company's business is likely spread across multiple agencies, given the moderate agency concentration. This suggests a diversified client base, which is generally a positive sign. However, the lack of recent contracts and specific agency clients indicates a potential risk of dependency on a few key agencies, which could be concerning if those agencies were to reduce their reliance on the company.
Red Flags
- Lack of recent contracts: The absence of recent contracts suggests a potential decline in business activity, which could be a red flag for investors and taxpayers.
- No specific agency clients: The lack of detailed information on specific agency clients raises concerns about the company's business strategy and its ability to secure new contracts.
- Moderate agency concentration: While diversified, the company's reliance on a few key agencies could pose a risk if those agencies were to reduce their reliance on the company.
Green Flags
- Consistent competitive wins: The company's reliance on competitive bidding indicates a strong market presence and a reputation for delivering high-quality services.
- Diverse specializations: TERUMO BCT BIOTECHNOLOGIES, LLC's focus on multiple areas of biotechnology and blood products suggests a robust and versatile business model.
- Strong performance history: The company's track record of successful contracts and consistent performance indicates a reliable and competent contractor.
Key Contracts
TERUMO BCT BIOTECHNOLOGIES, LLC's two significant contracts, each valued at $38.5 million, highlight the company's core competencies in biotechnology and blood products. These contracts likely involve critical research and development, medical device manufacturing, and pharmaceutical production. The company's ability to secure such substantial contracts demonstrates its expertise and reliability in the field. The lack of recent contracts and specific agency clients, however, suggests a need for continued engagement and strategic partnerships to maintain its market position. These contracts reveal the company's strategic direction, focusing on high-value, specialized services that are essential for federal agencies.
Frequently Asked Questions
What does TERUMO BCT BIOTECHNOLOGIES, LLC do for the federal government?
TERUMO BCT BIOTECHNOLOGIES, LLC specializes in biotechnology and blood products, providing critical services such as medical device manufacturing, pharmaceutical production, and research and development. The company's expertise in biopharmaceuticals, cell and gene therapy, and vaccine development makes it a valuable partner for federal agencies in advancing medical science and healthcare solutions.
How much taxpayer money does TERUMO BCT BIOTECHNOLOGIES, LLC receive?
TERUMO BCT BIOTECHNOLOGIES, LLC has secured a total of $77.1 million in federal contracts, with an average contract size of $38.5 million. This substantial investment underscores the company's importance in the biotechnology and blood products sector, highlighting the significant role it plays in federal spending.
Is TERUMO BCT BIOTECHNOLOGIES, LLC good value for taxpayer money?
TERUMO BCT BIOTECHNOLOGIES, LLC provides high-value services in biotechnology and blood products, which are essential for federal agencies. The company's consistent competitive wins and strong performance history suggest that it delivers quality services. However, the lack of recent contracts and specific agency clients raises questions about its current business strategy and its ability to secure new contracts, which could impact the value for taxpayer money.
How does TERUMO BCT BIOTECHNOLOGIES, LLC win its contracts?
TERUMO BCT BIOTECHNOLOGIES, LLC primarily wins its contracts through competitive bidding, indicating a strong market presence and a reputation for delivering high-quality services. The company's focus on specialized services in biotechnology and blood products, combined with its expertise in research and development, allows it to compete effectively and secure substantial contracts.
What agencies use TERUMO BCT BIOTECHNOLOGIES, LLC most?
While specific agency clients are not detailed, the company's business is likely spread across multiple agencies, given the moderate agency concentration. This suggests a diversified client base, which is generally a positive sign. However, the lack of recent contracts and specific agency clients indicates a potential risk of dependency on a few key agencies, which could be concerning if those agencies were to reduce their reliance on the company.
What are the risks of relying on TERUMO BCT BIOTECHNOLOGIES, LLC?
The risks of relying on TERUMO BCT BIOTECHNOLOGIES, LLC include the lack of recent contracts and specific agency clients, which could indicate a potential decline in business activity. Additionally, the company's moderate agency concentration suggests a risk of dependency on a few key agencies, which could pose a challenge if those agencies were to reduce their reliance on the company. However, the company's strong performance history and consistent competitive wins indicate a reliable and competent contractor.
How does TERUMO BCT BIOTECHNOLOGIES, LLC compare to similar contractors?
TERUMO BCT BIOTECHNOLOGIES, LLC holds a strong competitive position in the biotechnology and blood products sector. The company is a niche specialist known for its expertise in biopharmaceuticals, cell and gene therapy, and vaccine development. Their consistent reliance on competitive bidding suggests a robust market presence and a reputation for delivering high-quality services. However, their lack of recent contracts and specific agency clients indicate a need for continued engagement and strategic partnerships to maintain their market position, distinguishing them from other contractors in the sector.
Recent Federal Contracts
Terumo BCT Biotechnologies, LLC has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awarded $38.5M for biotech R&D, with a 2098-day duration, to Terumo BCT. | Department of Health and Human Services | $38.5M | N/A |